Related Experiment Video

Updated: Aug 19, 2026

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

TGFalpha expression impairs Trastuzumab-induced HER2 downregulation

Giorgio Valabrega1, Filippo Montemurro, Ivana Sarotto

  • 1Division of Medical Oncology, Institute for Cancer Research and Treatment, University of Turin Medical School, Str. Prov. 142, Km 3.95, 10060 Candiolo, Italy.

Oncogene
|March 1, 2005
PubMed

Insights

Trastuzumab resistance in HER2-positive breast cancer may stem from TGF-alpha, not HER2 downregulation defects. This discovery offers new avenues for overcoming treatment unresponsiveness in patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • HER2 (Human Epidermal growth factor Receptor 2) is a tyrosine kinase receptor overexpressed in 25-30% of breast cancers.
  • Trastuzumab, an anti-HER2 monoclonal antibody, shows efficacy in metastatic breast cancer but faces significant primary and acquired resistance.
  • Mechanisms of Trastuzumab resistance, particularly impaired HER2 downregulation, are not fully understood.

Purpose of the Study:

  • To investigate the role of mutations in HER2 and Cbl genes in Trastuzumab resistance.
  • To explore alternative mechanisms, such as TGF-alpha (Transforming Growth Factor alpha), contributing to Trastuzumab unresponsiveness.
  • To elucidate the impact of TGF-alpha on HER2 endocytosis and downregulation in breast cancer cells.

Main Methods:

  • Genomic sequencing of HER2 and Cbl genes in 63 breast cancer samples.
  • Analysis of TGF-alpha expression in paired tumor tissues before and after Trastuzumab treatment.
  • In vitro experiments involving exogenous TGF-alpha expression in breast cancer cells to assess its effect on Trastuzumab-induced HER2 endocytosis and downregulation.

Main Results:

  • No mutations were found in the critical HER2 and Cbl downregulation regions across the 63 breast cancer samples.
  • Induction of TGF-alpha expression was observed in neoplastic tissue after Trastuzumab treatment in selected cases.
  • In vitro, exogenous TGF-alpha significantly reduced Trastuzumab-induced HER2 endocytosis, downregulation, and cell growth inhibition.

Conclusions:

  • Trastuzumab unresponsiveness is not primarily due to intrinsic defects in the HER2 downregulation machinery.
  • TGF-alpha-mediated escape from HER2 downregulation represents a potential mechanism driving resistance to Trastuzumab therapy.
  • Targeting TGF-alpha pathways may offer a strategy to overcome Trastuzumab resistance in HER2-positive breast cancer.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Determining Optimal Cytotoxic Activity of Human Her2neu Specific CD8 T cells by Comparing the Cr51 Release Assay to the xCELLigence System11:31

Determining Optimal Cytotoxic Activity of Human Her2neu Specific CD8 T cells by Comparing the Cr51 Release Assay to the xCELLigence System

Published on: August 8, 2012

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...